Oncology ASCO 2024 - Mohit Manrao Just about everyone seems to agree that the runaway success story of ASCO this year is AstraZeneca, with plenary sessions for the sixth year in a row and
R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
